Research Progress in Interventional Therapy Combined with Targeted and Immunotherapy for Primary Liver Cancer
GAN Xinyi
DU Wenjun
Abstract：Primary hepatocellular carcinoma(HCC)has a high incidence rate,and most patients are already in the mid-to-late stage at the time of initial diagnosis.For the treatment of such HCC patients,the efficacy of a single treatment modality,whether it is transvascular interventional therapy,targeted therapy or immunotherapy,is not entirely satisfactory.With the continuous advancement of treatment technology,the triple combination therapy of interventional therapy,targeted therapy and immunotherapy has demonstrated synergy.By summarizing the current status of combination therapy at home and abroad,it is shown that combination therapy can improve the survival rate and efficacy of patients,prolong the survival time of patients,and effectively increase the surgical resection rate of patients with initially unresectable HCC,bringing new ideas to the treatment of HCC.This article analyzes the potential mechanisms related to combination therapy,and then briefly describes the main progress in terms of clinical application,adverse reactions and efficacy prediction,and proposes the current research difficulties and problems that urgently need to be solved.
Keywords：Liver cancerInterventional therapyImmunotherapyMolecular targeted therapy
Publication Date：2024-11-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1802-1806 )